In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Human Genetic Therapies Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.shire.com

Latest From Shire Human Genetic Therapies Inc.

Interview: Orchard's Gene Therapies Bear Fruit With $110m Financing

The UK firm has attracted more top-tier investors who are clearly impressed with its gene therapy for bubble baby syndrome and a high-quality pipeline in other very rare diseases.

Rare Diseases Financing

APPOINTMENTS: J&J, Adherium, Tizona Therapeutics, Pliant, ProclaRx, Biocom, FORMA, VAXIMM

This week’s announcements include board appointments by Biocom, Pliant Therapeutics and ProclaRx; senior appointments by FORMA Therapeutics and Tizona Therapeutics and various appointments in Asia by China Healthcare Reform Office, Shanghai Pharmaceuticals and the Johnson & Johnson Innovation Center in Shanghai.

Appointments BioPharmaceutical

Deal Terminations Not The End Of The Road For Licensed Drugs

Post-deal termination, approximately 14% of the drugs from those alliances go on to be approved, and of those still in development, nearly two-thirds advance at least one phase. Third in a series of follow-ups to IN VIVO’s 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.

BioPharmaceutical Deals

Unpacking Lysosomal Storage: New Insights Drive Parkinson’s Drug Development

Investors and dealmakers are using recent discoveries about convergences between Gaucher’s disease and Parkinson’s in the lysosome to generate new therapeutic programs. Start-up Lysosomal Therapeutics thinks that the rare disorder can serve as a model system for developing new drugs to increase lysosomal function as a way to treat Parkinson’s disease and possibly other neurodegenerative disorders.

BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Metabolic Disorders
  • Alias(es)
  • Transkaryotic Therapies Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Gregory D Perry, SVP, CFO
    John Conley, VP, Bus. Dev.
    John B Edwards, VP, Mktg.
    Whaijen Soo, MD, PhD, SVP, R&D
    Sylvie Gregoire, PhD, Pres.
  • Contact Info
  • Shire Human Genetic Therapies Inc.
    Phone: (617) 349-0200
    700 Main St.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register